GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

Grail Projected That the NHS-Galleri Trial Was Powered to Deliver a Statistically Significant Reduction in Late-Stage Cancers; Instead, the Primary Endpoint Was Not Observed, and Investors Lost $51.32 Per Share Grail Projected That the NHS-Galleri Trial Was Powered to Deliver a Statistically Significant Reduction in Late-Stage Cancers; Instead, the Primary Endpoint Was Not Observed, and Investors Lost $51.32 Per Share